Iambic Therapeutics (NASDAQ:IAM) Now Covered by Analysts at Bank of America

Research analysts at Bank of America assumed coverage on shares of Iambic Therapeutics (NASDAQ:IAM) in a research note issued to investors on Monday, MarketBeat reports. The firm set a “buy” rating and a $30.00 price target on the stock. Bank of America‘s price objective points to a potential upside of 194.99% from the company’s previous close.

Separately, Wall Street Zen raised Iambic Therapeutics to a “hold” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.67.

Iambic Therapeutics Stock Performance

Shares of IAM stock opened at $10.17 on Monday. Iambic Therapeutics has a 12-month low of $9.60 and a 12-month high of $25.00.

Insider Buying and Selling

In related news, Director Evan Lockwood Rachlin acquired 718,750 shares of the stock in a transaction on Friday, October 16th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $11,500,000.00. Following the transaction, the director owned 2,588,248 shares of the company’s stock, valued at $41,411,968. The trade was a 38.45% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

About Iambic Therapeutics